FDA grants Teva exclusive marketing rights for ‘morning after pill’

Teva’s brand of the pill will be the only non-prescription, over-the-counter version of the drug available.

July 24, 2013 23:27
1 minute read.
Teva Pharmaceutical plant is seen in Jerusalem

Teva 311. (photo credit: REUTERS/Ronen Zvulun)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The US Food and Drug Administration on Monday granted Teva Pharmaceuticals exclusive rights to market their Plan B One-Step contraceptive pill, commonly known as the “morning-after pill,” for three years.

Teva’s brand of the pill, which prevents pregnancy if taken within 72 hours of unprotected intercourse, will be the only non-prescription, over-the-counter version of the drug available.

Be the first to know - Join our Facebook page.

While the availability of the drug over-the-counter elicited cheers from reproductive-rights groups, the fact that cheaper, generic alternatives would be barred for several years drew criticism.

Having previously rejected Teva’s application for approval, the FDA approved the drug for women over the age of 15 in April. In June, it approved the drug for over-the-counter sale without restriction.

“Bringing Plan B One-Step out from behind the pharmacy counter helps women tremendously by removing one of the biggest barriers to access and timely use of emergency contraception, which is critically important.

Plan B One-Step allows women to get what they need with one dose, without waiting 12 hours to take a second pill to complete the regimen,” said Jill DeSimone, senior vice president and general manager, Teva Global Women’s Health.

According to FDA commissioner Margaret A. Hamburg, research showed that access to emergency contraception could potentially decrease the rate of unintended pregnancies.

“The data reviewed by the agency demonstrated that women 15 years of age and older were able to understand how Plan B One-Step works, how to use it properly and that it does not prevent the transmission of a sexually transmitted disease,” she said following the April approval.

According to Teva, nearly half of all pregnancies in the US are unplanned.

Of those pregnancies, which number 3.1 million annually, half of the women report having taken contraception during the month of conception.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection